## Nasdaq Regulation



Eun Ah Choi Senior Vice President Global Head of Regulatory Operations

November 12, 2024

Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549

Division of Corporation Finance:

This is to certify that on October 30, 2024, The Nasdaq Stock Market LLC (the "Exchange") received from Telix Pharmaceuticals Limited (the "Registrant") a copy of the Registrant's application on Form 20-F for the registration of the following security:

American depositary shares, each representing one ordinary share, no par value

Ordinary shares, no par value<sup>1</sup>

We further certify that the security described above has been approved by the Exchange for listing and registration upon official notice of issuance.

We understand that the Registrant is seeking immediate acceleration of the effective date of registration, and we hereby join in such request.

Sincerely,

En In Chri

<sup>&</sup>lt;sup>1</sup> Listed not for trading, but only in connection with the registration of the American Depositary Shares, pursuant to the requirements of the Securities & Exchange Commission.